Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD).

Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).

[1] The drug was approved in September 2020 in Japan for anemia associated with CKD[2] and is currently in clinical development in the United States and South Korea.

[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.

[4] This drug article relating to the blood and blood forming organs is a stub.